Interestingly, some protective factors, such as the use of mTOR inhibitors (e.g., everolimus) [6], HLA-B51 positivity [7], and ADPKD [8], have been associated with lower risks of BKPyV reactivation. Here, MTOR is linked to autosomal dominant polycystic kidney disease.